Abstract
Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Current Medicinal Chemistry
Title: Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects
Volume: 15 Issue: 10
Author(s): Naohiro Seo, Hiromichi Yamashiro and Toshimasa Tadaki
Affiliation:
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Abstract: Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Export Options
About this article
Cite this article as:
Seo Naohiro, Yamashiro Hiromichi and Tadaki Toshimasa, Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects, Current Medicinal Chemistry 2008; 15 (10) . https://dx.doi.org/10.2174/092986708784049603
DOI https://dx.doi.org/10.2174/092986708784049603 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lack of Interaction of the NMDA Receptor Antagonists Dextromethorphan and Dextrorphan with P-Glycoprotein
Current Drug Metabolism Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Coding and Non-coding: Molecular Portrait of GIST and its Clinical Implication
Current Molecular Medicine CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design Indolinones as Promising Scaffold as Kinase Inhibitors: A Review
Mini-Reviews in Medicinal Chemistry Peptide Targeted Copper-64 Radiopharmaceuticals
Current Topics in Medicinal Chemistry Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer
Current Pharmaceutical Design Childhood Solitary Cutaneous Mastocytoma: Clinical Manifestations, Diagnosis, Evaluation, and Management
Current Pediatric Reviews PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
Current Medicinal Chemistry MRI Contrast Agents: Current Status and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Avian Cytokines - An Overview
Current Pharmaceutical Design Gist Representations and Communication of Risks about HIV-AIDS: A Fuzzy-Trace Theory Approach
Current HIV Research